Medicxi Ventures Management (Jersey) LTD Phathom Pharmaceuticals, Inc. Transaction History
Medicxi Ventures Management (Jersey) LTD
- $481 Million
- Q3 2024
A detailed history of Medicxi Ventures Management (Jersey) LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Medicxi Ventures Management (Jersey) LTD holds 7,464,572 shares of PHAT stock, worth $56 Million. This represents 28.04% of its overall portfolio holdings.
Number of Shares
7,464,572
Previous 7,464,572
-0.0%
Holding current value
$56 Million
Previous $76.9 Million
75.53%
% of portfolio
28.04%
Previous 27.45%
Shares
5 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$75.8 Million9.84% of portfolio
-
Jennison Associates LLC5.87MShares$44 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$30.7 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$26.2 Million9.52% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$21.9 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $294M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...